EFTA00857649Set 9
2018-03-164p1,957w
oncology. The company is currently
developing drug product candidates: Tamsulosin DRS, slow release granules, and Tamsulosin XR capsules for
lower urinary tract symptoms of benign prostatic hyperplasia (BPH) (NDA planned ... Solifenacin DRG, slow
release granules, for overactive bladder (urge incontinence, urgency and frequency of urination) (NDA planned
2019), Tadalafil/finasteride combination tablet for restricted urination because of an enlarged prostate
https://www.justice.gov/epstein/files/DataSet%209/EFTA00857649.pdf